OverviewSuggest Edit

Immunovia engages in the development of a technology platform based on antibody microarray analysis. It focuses on developing diagnosis of cancer and autoimmune diseases. The Company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. It also provides IMMray Proteome Survey platform, a discovery tool for proteome scanning. 

TypePublic
Founded2007
HQLund, SE
Websiteimmunovia.com

Latest Updates

Employees (est.) (Feb 2021)67
Share Price (Feb 2021)KR116.4 (+5%)
Cybersecurity ratingAMore

Key People/Management at Immunovia

Rolf Ehrnström

Rolf Ehrnström

Chief Scientific Officer
Mimmi Ekberg

Mimmi Ekberg

Director
Carl Borrebaeck

Carl Borrebaeck

Chairman of the Board
Patrik Dahlen

Patrik Dahlen

Chief Executive Officer
Hans Liljenborg

Hans Liljenborg

Chief Financial Officer
Laura Chirica

Laura Chirica

Chief Commercial Officer
Show more

Immunovia Office Locations

Immunovia has offices in Lund, Marlborough and Frankfurt am Main
Lund, SE (HQ)
Medicon Village Scheelevägen 2
Lund, SE
Scheelevägen 2
Frankfurt am Main, DE
Herriotstraße 1
Marlborough, MA, US
26 Forest St #110, Marlborough
Show all (4)

Immunovia Financials and Metrics

Immunovia Revenue

Market capitalization (26-Feb-2021)

2.6b

Closing stock price (26-Feb-2021)

116.4
Immunovia's current market capitalization is kr2.6 b.
Show all financial metrics

Immunovia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Immunovia Online and Social Media Presence

Embed Graph

Immunovia News and Updates

Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021

LUND, Sweden, Feb. 10, 2021 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today provides an update on the status of the company's activities and as previously reported (Webinar Dec 17, 2020), Immunovia will initiate sales start in Q1 2021 of the company's first test, IMMray™ PanCan-d...

Nomination Committee appointed for the 2021 Annual General Meeting of Immunovia AB (Publ)

LUND, Sweden, Nov. 11, 2020 /PRNewswire/ -- The Nomination Committee, which is to be appointed for the period until a new Nomination Committee is appointed, shall consist of four members, of which three will be appointed by the Company's three largest shareholders in terms of voting, and...

Immunovia Provides Complementary Information on the IMMray™ PanCan-d Verification and Validation Studies

LUND, Sweden, Oct. 27, 2020 /PRNewswire/ -- Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced a necessary clarification to supplement the information shared on 26 October 2020 (link to press...

Immunovia Announces Positive Results from the IMMray™ PanCan-d Verification Study

LUND, Sweden, Sept. 29, 2020 /PRNewswire/ -- Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced positive results from the verification study and will now commence the validation study, the...

Summary from The Extraordinary General Meeting of Immunovia

STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- Extraordinary General Meeting of Immunovia AB (publ), Corp. Reg. No. 556730-4299 was held at The Spark in Medicon Village, Scheeletorget 1, Lund, Sweden, on September 23, 2020. A summary of the decisions taken is presented below. Election of new...

Immunovia Announces Management Team Changes

LUND, Sweden, Sept. 2, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Dr. Peter...
Show more

Immunovia Blogs

Poster: Commercial Test Model Study – A multicenter survey

Payam Delfani, Anders Carlsson, Thomas King, Randall Brand, Alexander Ney, Stephen P Pereira, A. James Moser, Genesis Perez-Melara, Corinne DeCicco, Alfredo Carrato, María E. Castillo-Sánchez, Julie Earl, Linda Dexlin Mellby Acknowledgements: Immunovia would like to acknowledge, Diane M. Simone, MD,…

Poster: Optimization Study – Differentiating pancreatic cancer from individuals with concerning symptoms, including type II diabetes

Payam Delfani, Anders Carlsson, Thomas King, Randall Brand, Alexander Ney, Stephen P Pereira, Linda Dexlin Mellby The IMMray™ PanCan-d optimization study was finalized 2019. Click here to read the complete poster (pdf), Jan 2021 The post Poster: Optimization Study – Differentiating pancreatic cancer…

Immunovia walks around the world to raise awareness for pancreatic cancer

In the United States, Pancreatic Ductal Adenocarcinoma (PDAC) has surpassed breast cancer as the third deadliest cancer with an increasing mortality rate. PDAC is projected to become the second most deadly cancer by 2030. The high mortality rate is primarily due to the late detection of PDAC and its…

The European Commission article on Immunovia’s IMMray PanCan-d test and the highly successful results of the Horizon 2020 IMMPACT project

Link to European Commission article. More information about the Horizon 2020 project. The post The European Commission article on Immunovia’s IMMray PanCan-d test and the highly successful results of the Horizon 2020 IMMPACT project appeared first on Immunovia.

Immunovia joins ”Light it purple” initiative on World Pancreatic Cancer Day

November 21, 2019 marks World Pancreatic Cancer Day (WPCD), when all of us around the world should raise awareness of the signs and symptoms of pancreatic cancer, which currently has the lowest survival rate of any cancer. The symptoms of pancreatic cancer can be vague and non-specific. As a result,…

Immunovia’s pancreatic cancer awareness campaign airs in Times Square, New York City

Immunovia’s new video, highlighting the importance of early detection in pancreatic cancer, will air today in the heart of Times Square in New York City. The campaign will run approximately three times an hour through September 30, 2019 on the “Bowtie Screen” located at the corner of 1500 Broadway a…
Show more

Immunovia Frequently Asked Questions

  • When was Immunovia founded?

    Immunovia was founded in 2007.

  • Who are Immunovia key executives?

    Immunovia's key executives are Rolf Ehrnström, Mimmi Ekberg and Carl Borrebaeck.

  • How many employees does Immunovia have?

    Immunovia has 67 employees.

  • Who are Immunovia competitors?

    Competitors of Immunovia include Anixa Biosciences, Prime Genomics and Predicine.

  • Where is Immunovia headquarters?

    Immunovia headquarters is located at Medicon Village Scheelevägen 2, Lund.

  • Where are Immunovia offices?

    Immunovia has offices in Lund, Marlborough and Frankfurt am Main.

  • How many offices does Immunovia have?

    Immunovia has 4 offices.